ArticleBMC cancer2026
A preliminary study on the prognostic impact of platelet to monocyte ratio and its related genes on non-small cell lung cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Activated Platelets Express GPI-Anchored Fibrocystin-L (PKHD1L1), from Granules, Absent or Deficient in Paroxysmal Nocturnal Hemoglobinuria.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeImpact of pre-treatment platelet-monocyte ratio on prognosis in patients with non-small cell lung cancer. 2. Screening and analyzing the relationship between NSCLC, platelet- and monocyte-associated genes and prognosis. 3. Expression of platelet- and monocyte-associated genes in NSCLC and the correlation between them and clinicopathological features and survival time.
methodsThe clinicopathological characteristics of the high and low PMR groups were compared by t-test and chi-square test. The Cox proportional hazards regression model was used to analyze univariate and multivariate factors, and statistical analysis was conducted using R language statistical software. The optimal PMR was obtained by using the surv_cutpoint function of the "survminer" software package. The optimal cut-off point of PMR was obtained by using the surv_cutpoint function of the "survminer" software package, and univariate and multivariate analyses were conducted by using its "Survival" software package. The survival data were fitted using the survfit function of the "survival" package, the survival curve was plotted using the ggsurvplot function of the "survival" package, and the cox regression model was constructed using the coxph function of the "survival" package. 2. The cox regression model was constructed using the coxph function of the "Survival" software package. The "limma" software package was used to perform deg analysis on tumor samples of patients and normal controls. Matching genes were used for single-gene COX regression analysis, gene grouping and KM survival analysis, etc. The ROC curve was used to evaluate the prognostic model test. 3. Laboratory verification: The expression of the target gene was observed by qPCR experiment. The correlation between the staining of the target gene and the clinicopathological characteristics and survival time was detected by immunohistochemical experiment. The experimental results were analyzed by SPSS and Graphpad Prism software.
resultsPMR is closely related to various clinicopathological characteristics of NSCLC patients. PMR is an independent risk factor for OS in patients with NSCLC. 2. We identified five genes independently associated with the prognosis of non-small cell lung cancer through analysis: FSTL3, MYLIP, PKHD1L1, C8B and EREG. Compared with adjacent tissues, the expression of these five genes was consistently and significantly downregulated in tumor tissues.
conclusionsPMR value may be a potential prognostic indicator for non-small cell lung cancer. Combining PMR with clinicopathological characteristics, it can be considered to further refine the treatment and prognosis plans for patients based on this proportion. 2. These key genes are all related to the process of tumor occurrence and development, providing a basis for the early and accurate diagnosis of NSCLC patients and promising the discovery of potential targets for tumor treatment. 3. The FSTL3, MYLIP, ppkhd1l1 and C8B genes in NSCLC tissues may be potential carcinogenic factors, potential biological markers and potential targets for the treatment of NSCLC tumors, and EREG may be a biomarker with significant prognostic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.